Conferences - Results from #10640

Viewing 10641-10660 of 11879 articles

#ASCO14 - Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study - Session Highlights

#ASCO14 - Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer (UBC) - Session Highlights

Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer

#ASCO14 - Poster: Circulating tumor cell count and lactate dehydrogenase levels are prognostic factors in patients with metastatic CRPC progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial

#ASCO14 - Poster: ARN-509 in patients with metastatic castration-resistant prostate cancer with and without prior abiraterone acetate treatment

#ASCO14 - Poster: Phase 1b study of abiraterone acetate and docetaxel in patients with metastatic castration-resistant prostate cancer

#ASCO14 - Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) - Session Highlights

Early, phone-based, palliative care support improves caregiver quality of life

Discontinuing statins near the end of life is safe, improves patient quality of life

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing

#AUA14 - AUA Guideline: Medical management of kidney stones - Slide Presentation

#AUA14 - Poster: Retrospective evaluation of efficacy and safety of Argus sling for treatment of male stress urinary incontinence: The Canadian experience

#AUA14 - Poster: Stress urinary incontinence outcomes following transvaginal sling incision

#AUA14 - Poster: Sexual dysfunction and dyspareunia in the setting of vaginal mesh exposure

#AUA14 - Poster: Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection

#AUA14 - AUA Guideline: Diagnosis and treatment of overactive bladder (non-neurogenic)

#AUA14 - Poster: Multicenter validation study of a tissue epigenenic assay to predict histopathologically cancer-negative repeat prostate biopsies

#AUA14 - Poster: Overactive bladder patients ≥ 65 years of age have a similar efficacy and safety profile with onabotulinumtoxinA as patients less than 65 years of age

#AUA14 - Poster: Long-term efficacy and safety of repeat onabotulinumtoxinA treatment in overactive bladder syndrome and urinary incontinence: Third interim analysis, median 2.4 years follow-up

#AUA14 - Poster: Reduction in urinary incontinence and improvement in quality of life with onabotulinumtoxinA in overactive bladder patients is unaffected by the use of clean intermittent catheterization or the presence of urinary tract infection

528
529
530
531
532
533
534
535
536
537